15.83
1.85 (13.23%)
| Previous Close | 13.98 |
| Open | 14.17 |
| Volume | 3,842,092 |
| Avg. Volume (3M) | 1,058,404 |
| Market Cap | 1,350,275,200 |
| Price / Sales | 112.24 |
| Price / Book | 146.93 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Operating Margin (TTM) | -1,135.42% |
| Diluted EPS (TTM) | -1.71 |
| Quarterly Revenue Growth (YOY) | 5.00% |
| Total Debt/Equity (MRQ) | 297.04% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -99.23 M |
| Levered Free Cash Flow (TTM) | -64.38 M |
| Return on Assets (TTM) | -37.66% |
| Return on Equity (TTM) | -203.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Liquidia Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -2.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.50 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 13.64% |
| % Held by Institutions | 65.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 43.00 (Jefferies, 171.64%) | Buy |
| Median | 38.50 (143.21%) | |
| Low | 31.00 (Wells Fargo, 95.83%) | Buy |
| Average | 37.75 (138.47%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 25.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 15 Aug 2025 | 43.00 (171.64%) | Buy | 25.95 |
| Raymond James | 13 Aug 2025 | 41.00 (159.00%) | Buy | 25.20 |
| Wells Fargo | 13 Aug 2025 | 31.00 (95.83%) | Buy | 25.20 |
| Needham | 12 Aug 2025 | 36.00 (127.42%) | Buy | 24.10 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Sep 2025 | Announcement | Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium |
| 27 Aug 2025 | Announcement | Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference |
| 12 Aug 2025 | Announcement | Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 05 Aug 2025 | Announcement | Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 |
| 23 Jun 2025 | Announcement | Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |